Literature DB >> 12588512

Serotonin receptors involved in vasopressin and oxytocin secretion.

H Jørgensen1, M Riis, U Knigge, A Kjaer, J Warberg.   

Abstract

Serotonin (5-HT), 5-HT agonists, the 5-HT precursor 5-hydroxytryptophan, 5-HT-releasers and -reuptake inhibitors stimulate the release of vasopressin and oxytocin. We investigated the involvement of 5-HT receptors in the serotonergic regulation of vasopressin and oxytocin secretion. Vasopressin and oxytocin secretion was stimulated by 5-HT, the 5-HT(1A+1B+5A+7) agonist 5-carboxamidotryptamine (5-CT), the 5-HT(2A+2C) agonist DOI, the 5-HT(2C+2A) agonist mCPP, the 5-HT(2C) agonist MK-212, the 5-HT(3) agonist SR 57277 and the 5-HT(4) agonist RS 67506. The 5-HT(1A) agonist 8-OH-DPAT, which had no effect on vasopressin secretion, stimulated oxytocin secretion. The 5-HT-induced release of vasopressin and oxytocin was inhibited by central infusion of the 5-HT antagonists WAY 100635 (5-HT(1A)), LY 53857 (5-HT(2A+2C)), ICS 205-930 (5-HT(3+4)) and RS 23597 (5-HT(4)). The 5-HT2+6+7 antagonist metergoline in combination with the 5-HT1A+2+7 antagonist methysergide inhibited the stimulatory effect of 5-CT on both hormones, whereas the 5-HT1A+1B antagonist cyanopindolol only inhibited the oxytocin response. The 5-HT(2A) antagonist 4-(4-flourobenzoyl)-1-(4-phenylbutyl)-piperidine oxalate had no effect on DOI-induced hormone response. The 5-HT(2C) antagonist Y 25130 partly inhibited the stimulating effect of MK-212. ICS 205-930 and RS 23597 inhibited vasopressin and oxytocin secretion induced by RS 67506. WAY 100635 inhibited 8-OH-DPAT-induced oxytocin secretion. We conclude that 5-HT-induced vasopressin secretion primarily is mediated via 5-HT(2C), 5-HT(4) and 5-HT(7) receptors, whereas 5-HT(2A), 5-HT(3) and 5-HT(5A) receptors seem to be of minor importance. 5-HT-induced oxytocin secretion involves 5-HT(1A), 5-HT(2C) and 5-HT(4) receptors; in addition an involvement of 5-HT(1B), 5-HT(5A) and 5-HT(7) receptors seems likely, whereas 5-HT(2A) and 5-HT(3) receptors seem to be less important.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588512     DOI: 10.1046/j.1365-2826.2003.00978.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  46 in total

1.  Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems.

Authors:  Elizabeth Hammock; Jeremy Veenstra-VanderWeele; Zhongyu Yan; Travis M Kerr; Marianna Morris; George M Anderson; C Sue Carter; Edwin H Cook; Suma Jacob
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-26       Impact factor: 8.829

2.  [A 67-year-old patient with somnolence and severe hyponatraemia].

Authors:  J Seiderer; C Rust; M Menth; T Pusl; M Jung
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

Review 3.  Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.

Authors:  Dennis H Kim; Matthew J Maneen; Stephen M Stahl
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

4.  Serotoninergic effects on judgments and social learning of trustworthiness.

Authors:  Arndis Simonsen; Jørgen Scheel-Krüger; Mads Jensen; Andreas Roepstorff; Arne Møller; Chris D Frith; Daniel Campbell-Meiklejohn
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

5.  Ghrelin-Induced Enhancement of Vasopressin and Oxytocin Secretion in Rat Neurohypophyseal Cell Cultures.

Authors:  M Gálfi; M Radács; Zs Molnár; I Budai; G Tóth; A Pósa; K Kupai; Z Szalai; R Szabó; H A Molnár; J Gardi; Ferenc A László; Cs Varga
Journal:  J Mol Neurosci       Date:  2016-10-17       Impact factor: 3.444

6.  Role of vasopressin V1a receptor in ∆9-tetrahydrocannabinol-induced cataleptic immobilization in mice.

Authors:  Nobuaki Egashira; Emi Koushi; Takayuki Myose; Akito Tanoue; Kenichi Mishima; Ryota Tsuchihashi; Junei Kinjo; Hiroyuki Tanaka; Satoshi Morimoto; Katsunori Iwasaki
Journal:  Psychopharmacology (Berl)       Date:  2017-09-14       Impact factor: 4.530

Review 7.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

8.  Refining the Candidate Environment: Interpersonal Stress, the Serotonin Transporter Polymorphism, and Gene-Environment Interactions in Major Depression.

Authors:  Suzanne Vrshek-Schallhorn; Susan Mineka; Richard E Zinbarg; Michelle G Craske; James W Griffith; Jonathan Sutton; Eva E Redei; Kate Wolitzky-Taylor; Constance Hammen; Emma K Adam
Journal:  Clin Psychol Sci       Date:  2013-08-26

9.  Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.

Authors:  Linnet Ramos; Callum Hicks; Richard Kevin; Alex Caminer; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Neuropsychopharmacology       Date:  2013-05-16       Impact factor: 7.853

Review 10.  Physiological regulation of magnocellular neurosecretory cell activity: integration of intrinsic, local and afferent mechanisms.

Authors:  C H Brown; J S Bains; M Ludwig; J E Stern
Journal:  J Neuroendocrinol       Date:  2013-08       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.